NanoViricides, Inc. (NNVC.PK) Signs Agreement With Viroclinics Biosciences BV For Testing Of Various Nanoviricides Against Specific Viruses Of Current Concern
2/4/2014 9:07:59 AM
WEST HAVEN, Conn.--(BUSINESS WIRE)--Tuesday, February 4th, 2014 - NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reported today that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences, BV (“Viroclinics”), a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides® , such as FluCide™, against viruses of mutual interest to both organizations.
Help employers find you! Check out all the jobs and post your resume.
comments powered by